Equibles does not estimate personal net worth.
Get an email with a short summary when AbCellera Biologics Inc. publishes a filing, an earnings call transcript or a press release.
Get ABCL alertsAndrew Booth is recorded as CFO at AbCellera Biologics Inc. (ABCL). The newest filing on record that lists Andrew Booth as CFO at AbCellera Biologics Inc. (ABCL) is dated April 29, 2026. The proxy statement of AbCellera Biologics Inc. reports total compensation of $3,382,244 for Andrew Booth in fiscal 2025, including a base salary of $485,000. Disclosed compensation is on record for 5 fiscal years. Andrew Booth has spoken on 24 earnings calls and 2 other investor events across 1 company, most recently for AbCellera Biologics Inc. on November 9, 2026. AbCellera Biologics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at AbCellera Biologics Inc. includes Ester Falconer (CTO), Véronique Lecault (CTO), Andrew W. Lo (Board Member) and 5 others.
“As Carl pointed out, Epcelera continues to be in a strong liquidity position with over $790 million in cash and equivalents, and with over $100 million in available committed government funding to execute on our strategy.”
“As Carl pointed out, Abcelera continues to be in a strong liquidity position with over $565 million in cash and equivalents and with roughly $110 million in available committed government funding to execute on our strategy.”
“The Astellas and Bayer actually have kind of blazed the trail for us here. And what we're looking for is a statistically significant and clinically meaningful reduction in the frequency and severity of hot flashes at the four-week endpoint.”
“As Carl pointed out, Upsellera continues to be in a strong liquidity position with approximately $530 million in cash and equivalents and with roughly $125 million in available committed government funding to execute on our strategy.”
“So happy to spend a half an hour here and walk you through Abselra and the company. Just the standard legal disclaimer, I loved Ken's comment earlier today. I'm planning on making forward-looking statements, so you should check the SEC submissions for a full set of risks.”
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | AbCellera Biologics Inc. (ABCL) | Chief Financial Officer | $485,000 | $3,382,244 |
| 2024 | AbCellera Biologics Inc. (ABCL) | Chief Financial Officer | $460,000 | $3,428,578 |
| 2023 | AbCellera Biologics Inc. (ABCL) | Chief Financial Officer | $460,000 | $674,555 |
| 2022 | AbCellera Biologics Inc. (ABCL) | Chief Financial Officer | $450,000 | $4,887,682 |
| 2021 | AbCellera Biologics Inc. (ABCL) | Chief Financial Officer | $400,000 | $4,313,387 |
